DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?

Information source: Baqiyatallah Medical Sciences University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Obstructive Pulmonary Disease

Intervention: Macrolid, Theophylline, Inhaler Corticosteroids (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Baqiyatallah Medical Sciences University

Summary

Critical combination of various approved drugs in management for patients suffering with COPD.

Clinical Details

Official title: Combination of Approved Drug in COPD

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: 15% increasing in forced expiratory volume in 1 second

Eligibility

Minimum age: 22 Years. Maximum age: 86 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- current or past smoker COPD

Exclusion Criteria:

- history of significant occupational or other environmental exposures or a connective

tissue disease

Locations and Contacts

Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University, Mollasadra St,, Tehran 19945-546, Iran, Islamic Republic of
Additional Information

Starting date: February 2008
Last updated: November 6, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017